PCSK9
Proprotein convertase subtilisin/kexin type 9
The protein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene located on human chromosome 1. It is the ninth member of the protein convertase family, a group of enzymes that can activate homologous genes found in many species[1]. PCSK9 is a liver-synthesized protease that plays a major role in regulating the levels of low-density lipoprotein receptors (LDLR) on the surface of liver cells and can inhibit the LDLR recycling pathway. PCSK9 binds to LDLR on the surface of liver cells, escorts LDLR to lysosomes for degradation, and prevents LDLR from recirculating to the cell membrane, effectively increasing the level of circulating LDL. Therefore, inhibiting the activity of the PCSK9 protease can down-regulate circulating LDL levels. PCSK9 is closely associated with various cardiovascular diseases, especially hypercholesterolemia and atherosclerosis[2].
All Product Categories
-
PCSK9 Related Products (99)
Related Products (99)
-
PF-06815345
0 ImagesCat. No.: HY-112598CAS No.: 1900686-46-5
-
Bezeparsen sodium
0 ImagesCat. No.: HY-147252ABezeparsen sodium is a PCSK9 synthesis inhibitor.
-
Tafolecimab
0 ImagesCat. No.: HY-P99552CAS No.: 2225109-03-3Synonyms: IBI-306Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia.
-
Ticalicibart
0 ImagesTicalicibart is a humanized IgG4κ monoclonal antibody inhibitor targeting PCSK9. Ticalicibart has anti-hyperlipidaemic activity. Ticalicibart can be used for cardiovascular disease like hypercholesterolaemia research.
-
PCSK9-IN-29
0 ImagesPCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity.
-
CVI-LM001
0 ImagesCat. No.: HY-148626CVI-LM001 is an inhibitor PCSK 9. CVI-LM001 inhibits the interaction of PCSK9 with low-density lipoprotein receptor (LDLR), regulates the level of low-density lipoprotein cholesterol (LDL-C) in the blood, and exhibits lipid-lowering efficacy.
-
Bezeparsen
0 ImagesCat. No.: HY-147252CAS No.: 2639640-84-7Bezeparsen is a PCSK9 synthesis inhibitor.
-
Anti-PCSK9 Antibody
0 ImagesCat. No.: HY-P990485Purity: 98.39%Anti-PCSK9 Antibody is a human antibody expressed in CHO, targeting PCSK9. Anti-PCSK9 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-PCSK9 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
-
PCSK9 modulator-2
0 ImagesCat. No.: HY-128334CAS No.: 2365416-53-9PCSK9 modulator-2 (Compound 1) is a potent modulator of PCSK9 with an EC50 value of 202 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-2 has the potential for the research of hyperlipidemia.
-
PCSK9-IN-16
0 ImagesCat. No.: HY-153452CAS No.: 2455424-51-6PCSK9-IN-16 is a potent PCSK9 inhibitor. PCSK9-IN-16 is extracted from patent WO2020150474, example 87, has the potential for hypercholesterolemia and other cardiovascular diseases research.
-
MEDI-4166
0 ImagesCat. No.: HY-P992407MEDI-4166 is an antibody-peptide gene fusion molecule of a PCSK9 antibody and a GLP-1 analog. MEDI-4166 is applicable to research related to type 2 diabetes.
-
SPC5001 sodium scrambled negative control
0 ImagesCat. No.: HY-148687CSPC5001 sodium scrambled negative control is the sequence scrambled negative control of SPC5001 sodium.
-
PCSK9-IN-34
0 ImagesCat. No.: HY-179106CAS No.: 3035306-81-8PCSK9-IN-34 is a small molecule PCSK9 inhibitor. PCSK9-IN-34 can be used for research on cardiovascular conditions.
-
SPC4061
0 ImagesCat. No.: HY-148689CAS No.: 1018108-22-9SPC4061 an antisense nucleotide, is a potent PCSK9 inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases.
-
PCSK9 modulator-3
0 ImagesCat. No.: HY-146084CAS No.: 2476490-18-1
-
SPC4061 sodium scrambled negative control
0 ImagesCat. No.: HY-148689CSPC4061 sodium scrambled negative control is the sequence scrambled negative control of SPC4061 sodium.
-
(R,R)-PCSK9 degrader 1
0 ImagesCat. No.: HY-130245ACAS No.: 2216703-12-5(R,R)-PCSK9 degrader 1 is an isomer of PCSK9 degrader 1 (HY-130245). (R,R)-PCSK9 degrader 1 is a HyT-like PCSK9 degrader (IC50 of 655.4 nM) , and its PCSK9-binding site does not interfere with the binding of PCSK9 to LDL receptor. (R,R)-PCSK9 degrader 1 can be used in the research of atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, and related cardiovascular and cardiometabolic diseases.
